Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

CBER’s “Boutique” Role: Fitting In Oncology Center of Excellence

This article was originally published in RPM Report

Executive Summary

FDA is close to announcing a new “Oncology Center of Excellence” to consolidate drug, biologic and device review functions in cancer. In the run up to the announcement, CBER has been stressing the need to preserve its culture and experience with novel manufacturing techniques.

Advertisement

Related Content

The Next Step In FDA Reform? Consolidated Drug/Device Groups Proposed By FOCR

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register